Cullinan Therapeutics, Inc.
Cullinan Therapeutics shares additional preclinical B cell depletion data for CLN-978, supporting clinical development across multiple autoimmune diseases, at ACR Convergence 2025.
CLN-978 led to rapid and deep B cell depletion in vitro and in vivo in multiple autoimmune diseases.
CAMBRIDGE, Mass., Oct. 25, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and cancer, will present new preclinical data for CLN-978, its novel investigational CD19xCD3 bispecific T cell engager.
These data will be presented at the American College of Rheumatology (ACR) Convergence 2025, being held in Chicago, Illinois, October 24-29, in a poster presentation session on October 28, 10:30 a.m.-12:30 p.m. CT (Poster Session C, Poster Number 2293).
Cullinan will also have a Booth (#1074) in the Exhibit Hall.
Author's summary: Cullinan Therapeutics presents new data for CLN-978.
More News
- The new age of pediatric medication awareness - Express Healthcare
- Why Experienced Lawyers Matter in a Personal Injury Case | NorthPennNow
- Battlefield 6 REDSEC battle royale to officially launch soon
- Budget jitters see construction forecasts plummet
- Why hasn’t Zohran Mamdani taken a position on the ballot proposals?
- Titans deal cornerback Roger McCreary to Los Angeles Rams for pick
- Jensen Ackles back on 'Tracker' 3.2 to amp up the suspense
- Adolescent Blood Sugar Control in Teens With Type 1 Diabetes Linked to Later Complications
- Battlefield 6's Battle Royale Mode Is Called REDSEC, Is Free-To-Play, And Launches Tomorrow
- Squatters, renters and adult children bringing down The Villages - Villages-News.com